A brief review on Kollidon
Abstract
Polyvinylpyrrolidone includes soluble and insoluble grades; soluble grades are synthesised by the mechanism of polymerization, the free radical polymerization into water by using hydrogen peroxide as an initiator, the mechanism which terminates the polymerisation reaction makes it probable to produce soluble polyvinylpyrrolidone of about any molecular weight. Cross-linked polymer shows yield through popcorn polymerisation of an N-vinylpyrrolidone which gets insoluble polyvinylpyrrolidone. Kollidon is in the market as a brand name for polyvinylpyrrolidone, kollidon family now is a set of common excipients based on polyvinylpyrrolidone for use in pharmaceutical industry. They have a great variety of applications in an oral formulation; the functions of oral formulation encompass fast disintegration, sustain drug release, solubility, bioavailability enhancement, and stabilize the active ingredient. Kollidon containing a mixture of polyvinyl acetate plus povidone are generally used in the formation of sustained release formulation. Owing to their high molecular weight, are recognized as a suitable vehicle for producing sustained release drug delivery system. In this review paper, applications of different grades of kollidon are organized in the form of tables and reviewed critically. Current literature of patents on kollidon based formulations is also presented.
DOI
https://doi.org/10.22270/jddt.v9i2.2539References
Bühler V. Kollidon - Products & Industries - Google Search [Internet]. BASF SE PharmaIngredients&S ervices 67056Ludwigshafen,Germany. 2008 [cited 2018 Nov 22]. p. 7–266. Available from: https://www.google.co.in/search?q=basf+kollidon&oq=basf+kollidon&aqs=chrome..69i57j0l5.5831j0j7&sourceid=chrome&ie=UTF-8
Kollamaram G, Croker DM, Walker GM, Goyanes A, Basit AW, Gaisford S. Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs. Int J Pharm [Internet]. 2018; 545(1–2):144–52. Available from: https://doi.org/10.1016/j.ijpharm.2018.04.055
Lim SM, Pang ZW, Tan HY, Shaikh M, Adinarayana G, Garg S. Enhancement of docetaxel solubility using binary and ternary solid dispersion systems. Drug Dev Ind Pharm. 2015;41(11):1847–55.
Piccinni P, Tian Y, McNaughton A, Fraser J, Brown S, Jones DS, et al. Solubility parameter-based screening methods for early-stage formulation development of itraconazole amorphous solid dispersions. J Pharm Pharmacol. 2016; 68(5):705–20.
Kollamaram G, Croker DM, Walker GM, Goyanes A, Basit AW, Gaisford S. Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs. Int J Pharm. 2018; 545(1–2):144–52.
Linka W, Kot M, Kołodziejczyk M. Application of synthetic and semisynthetic polymers (Kollidon K30 and hydroxypropylmethylcellulose) as carriers of ketoprofen in solid oral prolonged-release dosage forms. Polym Med [Internet]. 2017; 46(2):145–53. Available from: http://www.polimery.umed.wroc.pl/en/article/2016/46/2/145/
Fini A, Bergamante V, Ceschel GC, Ronchi C, de Moraes CAF. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008; 69(1):335–41.
Dashevsky A, Bussemer T, Mohamad A, Bodmeier R. Process and Formulation Variables Affecting the Performance of a Rupturable Capsule-Based Drug Delivery System with Pulsatile Drug Release. Drug Dev Ind Pharm. 2004; 30(2):171–9.
Alsulays BB, Park JB, Alshehri SM, Morott JT, Alshahrani SM, Tiwari R V., et al. Influence of molecular weight of carriers and processing parameters on the extrudability, drug release, and stability of fenofibrate formulations processed by hot-melt extrusion. J Drug Deliv Sci Technol [Internet]. 2015; 29:189–98. Available from: http://dx.doi.org/10.1016/j.jddst.2015.07.011
Linka W, Kot M, Kołodziejczyk M. Application of synthetic and semisynthetic polymers (Kollidon K30 and hydroxypropylmethylcellulose) as carriers of ketoprofen in solid oral prolonged-release dosage forms. Polym Med. 2017; 46(2):145–53.
Maroni A, Del Curto MD, Cerea M, Zema L, Foppoli A, Gazzaniga A. Polymeric coatings for a multiple-unit pulsatile delivery system: Preliminary study on free and applied films. Int J Pharm [Internet]. 2013; 440(2):256–63. Available from: http://dx.doi.org/10.1016/j.ijpharm.2012.05.075
Gonnissen Y, Remon JP, Vervaet C. Effect of maltodextrin and superdisintegrant in directly compressible powder mixtures prepared via co-spray drying. Eur J Pharm Biopharm. 2008; 68(2):277–82.
Friedrich H, Fussnegger B, Kolter K, Bodmeier R. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm. 2006; 62(2):171–7.
Maroni A, Del Curto MD, Cerea M, Zema L, Foppoli A, Gazzaniga A. Polymeric coatings for a multiple-unit pulsatile delivery system: Preliminary study on free and applied films. Int J Pharm. 2013; 440(2):256–63.
Loka NC, Saripella KK, Pinto CA, Neau SH. Use of extrusion aids for successful production of Kollidon®CL-SF pellets by extrusion–spheronization. Drug Dev Ind Pharm [Internet]. 2018; 44(4):632–42. Available from: http://dx.doi.org/10.1080/03639045.2017.1405975
Amelian A, Szekalska M, Wilczewska AZ, Basa A, Winnicka K. Preparation and characterization of orally disintegrating loratadine tablets manufactured with co-processed mixtures. Acta Pol Pharm - Drug Res. 2016;
Mishra SM, Rohera BD. An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine. Pharm Dev Technol. 2017; 22(7):889–903.
Sheshala R, Khan N, Darwis Y. Formulation and Optimization of Orally Disintegrating Tablets of Sumatriptan Succinate. Chem Pharm Bull (Tokyo) [Internet]. 2011; 59(8):920–8. Available from: http://joi.jlc.jst.go.jp/JST.JSTAGE/cpb/59.920?from=CrossRef
Loka NC, Saripella KK, Pinto CA, Neau SH. Use of extrusion aids for successful production of Kollidon®CL-SF pellets by extrusion–spheronization. Drug Dev Ind Pharm. 2018; 44(4):632–42.
Sheshala R, Khan N, Darwis Y. Formulation and Optimization of Orally Disintegrating Tablets of Sumatriptan Succinate. Chem Pharm Bull (Tokyo). 2011; 59(8):920–8.
Shergill M, Patel M, Khan S, Bashir A, McConville C. Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int J Pharm [Internet]. 2016; 497(1–2):3–11. Available from: http://dx.doi.org/10.1016/j.ijpharm.2015.11.029
Özgüney I, Shuwisitkul D, Bodmeier R. Development and characterization of extended release Kollidon® SR mini-matrices prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2009; 73(1):140–5.
Meulenaar J, Keizer RJ, Beijnen JH, Schellens JHM, Huitema ADR, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. J Pharm Sci. 2014; 103(2):478–84.
Sakr W, Alanazi F, Sakr A. Effect of Kollidon®SR on the release of Albuterol Sulphate from matrix tablets. Saudi Pharm J [Internet]. 2011; 19(1):19–27. Available from: http://dx.doi.org/10.1016/j.jsps.2010.11.002
Song SH, Chae BR, Sohn S Il, Yeom DW, Son HY, Kim JH, et al. Formulation of controlled-release pelubiprofen tablet using Kollidon®SR. Int J Pharm [Internet]. 2016; 511(2):864–75. Available from: http://dx.doi.org/10.1016/j.ijpharm.2016.07.074
Sahoo J, Murthy PN, Biswal S, Manik. Formulation of Sustained-Release Dosage Form of Verapamil Hydrochloride by Solid Dispersion Technique Using Eudragit RLPO or Kollidon®SR. AAPS PharmSciTech [Internet]. 2009; 10(1):27–33. Available from: http://www.springerlink.com/index/10.1208/s12249-008-9175-0
Arias JL, Gómez-Gallo A, Delgado Á V., Ruiz MA. Kollidon®SR colloidal particles as vehicles for oral morphine delivery in pain treatment. Colloids Surfaces B Biointerfaces. 2009; 70(2):207–12.
Palazi E, Karavas E, Barmpalexis P, Kostoglou M, Nanaki S, Christodoulou E, et al. Melt extrusion process for adjusting drug release of poorly water soluble drug felodipine using different polymer matrices. Eur J Pharm Sci [Internet]. 2018; 114:332–45. Available from: https://doi.org/10.1016/j.ejps.2018.01.004
Wiranidchapong C, Ruangpayungsak N, Suwattanasuk P, Shuwisitkul D, Tanvichien S. Plasticizing effect of ibuprofen induced an alteration of drug released from Kollidon SR matrices produced by direct compression. Drug Dev Ind Pharm. 2015; 41(6):1037–46.
Dzajkowska M, Hanna K, Anna M, Maja S, Dagmara D, Anna S, et al. Prolonged-release minitablets with carbamazepine – preliminary observations in vitro. J Pharm Pharmacol. 2017; 69(4):471–9.
Engineer S, Shao ZJ, Khagani NA. Temperature/humidity sensitivity of sustained-release formulations containing Kollidon® SR. Drug Dev Ind Pharm. 2004; 30(10):1089–94.
Grund J, Koerber M, Walther M, Bodmeier R. The effect of polymer properties on direct compression and drug release from water-insoluble controlled release matrix tablets. Int J Pharm [Internet]. 2014; 469(1):94–101. Available from: http://dx.doi.org/10.1016/j.ijpharm.2014.04.033
Shergill M, Patel M, Khan S, Bashir A, McConville C. Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int J Pharm. 2016; 497(1–2):3–11.
Sakr W, Alanazi F, Sakr A. Effect of Kollidon®SR on the release of Albuterol Sulphate from matrix tablets. Saudi Pharm J. 2011; 19(1):19–27.
Song SH, Chae BR, Sohn S Il, Yeom DW, Son HY, Kim JH, et al. Formulation of controlled-release pelubiprofen tablet using Kollidon®SR. Int J Pharm. 2016; 511(2):864–75.
Sahoo J, Murthy PN, Biswal S, Manik. Formulation of Sustained-Release Dosage Form of Verapamil Hydrochloride by Solid Dispersion Technique Using Eudragit RLPO or Kollidon®SR. AAPS PharmSciTech. 2009; 10(1):27–33.
Palazi E, Karavas E, Barmpalexis P, Kostoglou M, Nanaki S, Christodoulou E, et al. Melt extrusion process for adjusting drug release of poorly water soluble drug felodipine using different polymer matrices. Eur J Pharm Sci. 2018; 114:332–45.
Chmiel K, Knapik-Kowalczuk J, Jurkiewicz K, Sawicki W, Jachowicz R, Paluch M. A New Method to Identify Physically Stable Concentration of Amorphous Solid Dispersions (I): Case of Flutamide + Kollidon VA64. Mol Pharm. 2017; 14(10):3370–80.
Dreu R, Ilić I, Srčič S. Development of a multiple-unit tablet containing enteric-coated pellets. Pharm Dev Technol. 2011; 16(2):118–26.
Vojinović T, Medarević D, Vranić E, Potpara Z, Krstić M, Djuriš J, et al. Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine. Saudi Pharm J. 2018; 26(5):725–32.
Tres F, Treacher K, Booth J, Hughes LP, Wren SAC, Aylott JW, et al. Indomethacin-Kollidon VA64 Extrudates: A Mechanistic Study of pH-Dependent Controlled Release. Mol Pharm. 2016; 13(3):1166–75.
Maddineni S, Battu SK, Morott J, Majumdar S, Murthy SN, Repka MA. Influence of Process and Formulation Parameters on Dissolution and Stability Characteristics of Kollidon® VA 64 Hot-Melt Extrudates. AAPS PharmSciTech [Internet]. 2015; 16(2):444–54. Available from: http://link.springer.com/10.1208/s12249-014-0226-4
Chaudhary RS, Patel C, Sevak V, Chan M. Effect of Kollidon VA®64 particle size and morphology as directly compressible excipient on tablet compression properties. Drug Dev Ind Pharm [Internet]. 2018; 44(1):19–29. Available from: https://doi.org/10.1080/03639045.2017.1371735
Patel D, Kumar P, Thakkar HP. Lopinavir metered-dose transdermal spray through microporated skin: Permeation enhancement to achieve therapeutic needs [Internet]. Vol. 29, Journal of Drug Delivery Science and Technology. Elsevier Ltd; 2015. 173-180 p. Available from: http://dx.doi.org/10.1016/j.jddst.2015.07.004
Kolter K, Flick D. Structure and dry binding activity of different polymers, including Kollidon® VA 64. Drug Dev Ind Pharm. 2000; 26(11):1159–65.
Castellanos Gil E, Iraizoz Colarte A, Lara Sampedro JL, Bataille B. Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet. Eur J Pharm Biopharm. 2008; 69(1):303–11.
Solanki NG, Tahsin M, Shah A V., Serajuddin ATM. Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability. J Pharm Sci [Internet]. 2018; 107(1):390–401. Available from: https://doi.org/10.1016/j.xphs.2017.10.021
Rask MB, Knopp MM, Olesen NE, Holm R, Rades T. Influence of PVP/VA copolymer composition on drug-polymer solubility. Eur J Pharm Sci [Internet]. 2016; 85:10–7. Available from: http://dx.doi.org/10.1016/j.ejps.2016.01.026
Maddineni S, Battu SK, Morott J, Majumdar S, Murthy SN, Repka MA. Influence of Process and Formulation Parameters on Dissolution and Stability Characteristics of Kollidon® VA 64 Hot-Melt Extrudates. AAPS PharmSciTech. 2015; 16(2):444–54.
Chaudhary RS, Patel C, Sevak V, Chan M. Effect of Kollidon VA®64 particle size and morphology as directly compressible excipient on tablet compression properties. Drug Dev Ind Pharm. 2018; 44(1):19–29.
Patel D, Kumar P, Thakkar HP. Lopinavir metered-dose transdermal spray through microporated skin: Permeation enhancement to achieve therapeutic needs. Vol. 29, Journal of Drug Delivery Science and Technology. Elsevier Ltd; 2015. 173-180 p.
Nidhi K, Indrajeet S, Khushboo M, Gauri K, Sen DJ. Hydrotropy: A promising tool for solubility enhancement: A review. Int J Drug Dev Res. 2011; 3(2):26–33.
Solanki NG, Tahsin M, Shah A V., Serajuddin ATM. Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability. J Pharm Sci. 2018; 107(1):390–401.
Pilgaonkar P, Rustomjee M, Gandhi A, Jain P, Kelkar A. Patent Application Publication. Vol. 1. 2009.
Kanikanti V-R, Bach T, Traeubel M, Altreuther G, Rehagen M, Schmidt A. Patent Application Publication. Vol. 1. 2011.
Kolter K, Schonherr M, Ascherl H. United States Patent. Vol. 2. 2003.
Talwar N, Sen H, Staniforth J. United States Patent. Vol. 1. 2001.
Roser B, Blair J. United States Patent. 1998.
Bockbrader H, Cho Y, Santiago S, Mahjour M, Reynolds D, Shao P, et al. United States Patent. Vol. 2. 2015.
Published
Abstract Display: 3407 
PDF Downloads: 2862 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.